The treatment of osteoporosis: Antiresorptive therapy

Clinics in Laboratory Medicine

Volumn 20, Issue 3, 2000, Pages 603-622

  Miller, P D ^a  

^a University of Colorado Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; OSTEOPOROSIS; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0033838761     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0272-2712(18)30056-8     Document Type: Review

References (65)

1. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
2. The long term effects of estrogen therapy on bone mineral density: Evidence from the National Osteoporosis Risk Assessment (NORA) Program
3. Estrogen replacement therapy and fractures in older women
4. 3 and calcium to prevent hip fractures in the elderly women
5. Histomorphometric assessment of the long term effects of alendronate on bone quality and remodeling in patient with osteoporosis
6. Risedronate therapy prevents corticosteroid-induced bone loss
7. Bone density at various sites for prediction of hip fracture
8. Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women
9. Hip fracture prediction in the elderly men and women: Validation in the Rotterdam study
10. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
11. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis
12. Bone mineral content of amenorrheic and eumenorrheic athletes
13. Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease
14. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
15. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro
16. New bisphosphonates in osteoporosis
17. Bone remodeling and its relationship to metabolic bone disease
18. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
19. Ultrasonographic heel measurements to predict hip fracture in elderly women. The EPIDOS prospective study
20. Cyclical etidronate treatment of postmenopausal osteoporosis - 4 Year experience
21. The bone-remodeling transient: Implications for the interpretation of clinical studies of bone mass change
22. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
23. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
24. Short-term and long-term fracture prediction by bone mass measurements: A prospective study
25. Age and bone mass as predictors of fracture in a prospective study
26. Diagnosis of osteoporosis
27. Hip fracture and the use of estrogens in postmenopausal women
28. Risk assessment using bone mineral density determination
29. Long-term prevention of postmenopausal osteoporosis by oestrogen
30. Osteogenesis imperfecta - Managing brittle bones
31. Alendronate prevents postmenopausal bone loss in women without osteoporosis
32. Bone density and fracture risk in men
33. Determinants of bone loss from the femoral neck in women of different ages
34. Long-term fracture prediction by bone mineral assessed at different skeletal sites
35. Efficacy and safety of cyclical etidronate therapy in the long-term treatment of osteoporosis
36. Practical clinical application of biochemical markers of bone turnover
37. Clinical application of bone densitometry
38. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment
39. Alendronate treatment of osteoporosis in men
40. Does estrogen adequately protect postmenopausal women against osteoporosis: An iconoclastic perspective
41. A new model for the regulation of bone resorption with particular reference to the effects of bisphosphonates
42. Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: A prospective controlled hip fracture study with 206 consecutive patients
43. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations
44. Cyclical pamidronate infusions in postmenopausal osteoporosis
45. Correcting calcium nutritional deficiency prevents spine fractures in elderly women
46. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)
47. Incidence of hip fractures in osteoporotic women treated with sodium fluoride
48. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study
49. Bone mass homeostasis and bisphosphonate action
50. Osteoporosis after organ transplantation
51. Bisphosphonates are incorporated into adenine nucleotides by human amino-acyl-tRNA synthetase enzymes
52. Molecular mechanisms of action of bisphosphohates
53. Treatment of osteoporosis in postmenopausal women: Alendronate vs intranasal calcitonin
54. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
55. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
56. Age- and gender-specific rate of fracture in Australia: A population based study
57. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) in established osteoporosis and has continuing efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study
58. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women
59. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
60. Changes in cortical width with bone turnover in the three different endosteal envelopes of the ilium in postmenopausal osteoporosis
61. Effects of hormone therapy on bone mineral density
62. Bone mass measurement: Prediction of risk
63. Antifracture efficacy of antiresportive agents are related to changes in bone density
64. Intermittent cyclic etidronate treatment of postmenopausal osteoporosis
65. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids